Mga Batayang Estadistika
| CIK | 1823857 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common St
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: August 31, 2027 Estimated average burden hours per response....................1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECU |
|
| November 14, 2024 |
VHAQ / Viveon Health Acquisition Corp. / Meteora Capital, LLC Passive Investment SC 13G/A 1 meteoravhaq09302024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viveon Health Acquisition Corp. (Name of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 92853V106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| October 4, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Co |
|
| October 4, 2024 |
Viveon Health Acquisition Corp. Announces Liquidation of Trust Account Exhibit 99.1 Viveon Health Acquisition Corp. Announces Liquidation of Trust Account ATLANTA, Oct 4, 2024 – Viveon Health Acquisition Corp. (OTC: VHAQ, VHAQU) (the “Company”), today announced that it will redeem all of its outstanding shares of Class A common stock initially issued as part of the units sold in its initial public offering (the “Public Shares”), effective as of September 30, 2024, be |
|
| July 19, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commi |
|
| July 19, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commi |
|
| July 10, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Units, each consisting of 1 share of common stock, 1 Warrant entitling the holder to purchase 1/2 of a share of common stock, and 1 right to receive 1/20 of a share of common stock, the Rights, each exchangeable into one-twentieth of a share of Common Stock, and the Common Stock (the "Securities") of Viveon Health Acquisition Corp. |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH ACQUI |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 and May 12, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of inc |
|
| June 5, 2024 |
Exhibit 10.2 |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 and May 12, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of inc |
|
| June 5, 2024 |
Exhibit 10.2 |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Co |
|
| April 1, 2024 |
As filed Fourth Amendment to the Company’s Amended and Restated Certificate of Incorporation Exhibit 3.1 |
|
| April 1, 2024 |
As filed Fourth Amendment to the Company’s Amended and Restated Certificate of Incorporation Exhibit 3.1 |
|
| April 1, 2024 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Co |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Rep |
|
| March 27, 2024 |
Exhibit 10.1 NON-REDEMPTION AGREEMENT This Non-Redemption Agreement (this “Agreement”) is entered as of March 27, 2024, by and among Viveon Health Acquisition Corp., a Delaware corporation (“VHAQ” or the “Company”), Viveon Health LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned investor (collectively, the “Investor”). RECITALS WHEREAS, the Sponsor currently holds shar |
|
| March 27, 2024 |
Non-Redemption Agreement, dated March 27, 2024 Exhibit 10.1 NON-REDEMPTION AGREEMENT This Non-Redemption Agreement (this “Agreement”) is entered as of March 27, 2024, by and among Viveon Health Acquisition Corp., a Delaware corporation (“VHAQ” or the “Company”), Viveon Health LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned investor (collectively, the “Investor”). RECITALS WHEREAS, the Sponsor currently holds shar |
|
| March 27, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| March 27, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| March 15, 2024 |
NOTIFICATION OF THE FILING IN ERROR OF A FORM 25 WITH RESPECT TO THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") submitted a Form 25 (the "Original Form 25") on March 8, 2024 to notify the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Units, each consisting of 1 share of common stock, 1 Warrant entitling the holder to purchase 1/2 of a share of common stock, and 1 right to receive 1/20 of a share of common stock, the Rights, each exchangeable into one-twentieth of a share of Common Stock, and the Common Stock (the "Securities") of Viveon Health Acquisition Corp. |
|
| March 8, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Units, each consisting of 1 share of common stock, 1 Warrant entitling the holder to purchase 1/2 of a share of common stock, and 1 right to receive 1/20 of a share of common stock, the Rights, each exchangeable into one-twentieth of a share of Common Stock, and the Common Stock (the "Securities") of Viveon Health Acquisition Corp. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 27, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| February 27, 2024 |
VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS Exhibit 99.1 VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS New York, February 27, 2024 Viveon Health Acquisition Corp (NYSE American: VHAQ, VHAQR, VHAQU) a special purpose acquisition company (the “Company”) re-affirms its commitment to the previously announced business combination with Clearday (CLRD-OTCQX), a San Antonio, Texas-based Healthc |
|
| February 27, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| February 27, 2024 |
VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS Exhibit 99.1 VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS New York, February 27, 2024 Viveon Health Acquisition Corp (NYSE American: VHAQ, VHAQR, VHAQU) a special purpose acquisition company (the “Company”) re-affirms its commitment to the previously announced business combination with Clearday (CLRD-OTCQX), a San Antonio, Texas-based Healthc |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVE |
|
| February 21, 2024 |
Amendment to the Investment Management Trust Agreement, dated as of June 27, 2023. Exhibit 10.20 AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 3 (this “Amendment”), dated as of June 27, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the mea |
|
| February 21, 2024 |
Exhibit 10.21 Viveon Health Acquisition Corp. As of May 1, 2023 Reference is made to the following documents: i. The Subscription Agreement (the “Subscription Agreement”) between you and Viveon Health Acquisition Corp., a Delaware corporation (“Viveon”), relating to the Extension Note (as hereinafter defined) and the Extension Warrant (as hereinafter defined); ii. Senior Note due 2022 (as heretofo |
|
| February 21, 2024 |
Exhibit 4.7 DESCRIPTION OF SECURITIES OF VIVEON The following description of capital stock of Viveon Health Acquisition Corp. (“Viveon”, or the “Company”) and provisions of Viveon’s current amended and restated certificate of incorporation, as amended (the “Existing Charter”), bylaws and the Delaware General Corporation Law (“DGCL”) are summaries and are qualified in their entirety by reference to |
|
| February 21, 2024 |
Exhibit 10.22 THIS PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS, AND HAS BEEN ISSUED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH LAWS, INCLUDING, WITHOUT LIMITATION, THE EXEMPTION CONTAINED IN SECTION 4(a)(2) OF THE SECURITIES ACT |
|
| February 21, 2024 |
Exhibit 10.23 |
|
| February 21, 2024 |
Amendment to the Investment Management Trust Agreement, dated as of January 20, 2023. Exhibit 10.19 AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 2 (this “Amendment”), dated as of January 20, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the |
|
| February 14, 2024 |
VHAQ / Viveon Health Acquisition Corp. / Meteora Capital, LLC Passive Investment SC 13G/A 1 meteoravhaq123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveon Health Acquisition Corp. (Name of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 92853V106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2024 |
VHAQ / Viveon Health Acquisition Corp. / FIR TREE CAPITAL MANAGEMENT LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 5, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| January 5, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| December 26, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 22, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| November 22, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re |
|
| November 1, 2023 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Warrants to purchase one-half of a share of common stock at a price of $11. |
|
| August 29, 2023 |
Exhibit 2.1 FIRST AMENDMENT TO MERGER AGREEMENT This First Amendment to Merger Agreement (this “Amendment”), dated as of August 28, 2023 is entered into by and among Clearday, Inc., a Delaware corporation (the “Company”), Viveon Health Acquisition Corp., a Delaware corporation (“Parent”), VHAC2 Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Viveon Health LLC, a Delaware limited liability |
|
| August 29, 2023 |
Exhibit 2.1 FIRST AMENDMENT TO MERGER AGREEMENT This First Amendment to Merger Agreement (this “Amendment”), dated as of August 28, 2023 is entered into by and among Clearday, Inc., a Delaware corporation (the “Company”), Viveon Health Acquisition Corp., a Delaware corporation (“Parent”), VHAC2 Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Viveon Health LLC, a Delaware limited liability |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2023 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2023 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2023 |
Exhibit 99.1 Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement Norcross GA and San Antonio, TX (Aug. 29, 2023) (GLOBE NEWSWIRE) —Viveon Health Acquisition Corp. (NYSE American: VHAQ) (“Viveon”), a special purpose acquisition company, and Clearday, Inc. (CLRD) (“Clearday”), an innovative longevity technology company using an integrated platfo |
|
| August 29, 2023 |
Exhibit 99.1 Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement Norcross GA and San Antonio, TX (Aug. 29, 2023) (GLOBE NEWSWIRE) —Viveon Health Acquisition Corp. (NYSE American: VHAQ) (“Viveon”), a special purpose acquisition company, and Clearday, Inc. (CLRD) (“Clearday”), an innovative longevity technology company using an integrated platfo |
|
| August 24, 2023 |
Amendment to the Investment Management Trust Agreement, dated as of June 27, 2023. Exhibit 10.20 AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 3 (this “Amendment”), dated as of June 27, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the mea |
|
| August 24, 2023 |
Exhibit 4.7 DESCRIPTION OF SECURITIES OF VIVEON The following description of capital stock of Viveon Health Acquisition Corp. (“Viveon”, or the “Company”) and provisions of Viveon’s current amended and restated certificate of incorporation, as amended (the “Existing Charter”), bylaws and the Delaware General Corporation Law (“DGCL”) are summaries and are qualified in their entirety by reference to |
|
| August 24, 2023 |
Amendment to the Investment Management Trust Agreement, dated as of January 20, 2023. Exhibit 10.19 AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 2 (this “Amendment”), dated as of January 20, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the |
|
| August 24, 2023 |
Exhibit 10.23 |
|
| August 24, 2023 |
Unsecured Promissory Note (Clearday, Inc.) Exhibit 10.22 THIS PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS, AND HAS BEEN ISSUED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH LAWS, INCLUDING, WITHOUT LIMITATION, THE EXEMPTION CONTAINED IN SECTION 4(a)(2) OF THE SECURITIES ACT |
|
| August 24, 2023 |
Exhibit 10.21 Viveon Health Acquisition Corp. As of May 1, 2023 Reference is made to the following documents: i. The Subscription Agreement (the “Subscription Agreement”) between you and Viveon Health Acquisition Corp., a Delaware corporation (“Viveon”), relating to the Extension Note (as hereinafter defined) and the Extension Warrant (as hereinafter defined); ii. Senior Note due 2022 (as heretofo |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVEON HEALTH ACQUISITIO |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| June 27, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| June 27, 2023 |
Exhibit 3.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIVEON HEALTH ACQUISITION CORP. Pursuant to Section 242 of the Delaware General Corporation Law The undersigned, being a duly authorized officer of VIVEON HEALTH ACQUISITION CORP., (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows: 1. The name of |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Co |
|
| April 25, 2023 |
Viveon Health Acquisition Corp. Receives NYSE Notice Regarding Delayed Form 10-K Filing Exhibit 99.1 Viveon Health Acquisition Corp. Receives NYSE Notice Regarding Delayed Form 10-K Filing New York, April 25, 2023 — Viveon Health Acquisition Corp. (Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (the “Company”) announced today, that on April 18, 2023, the Company received a notice letter (the “Notice”) from the NYSE Regulation Department (the “Staff”) of th |
|
| April 11, 2023 |
Exhibit 10.2 COMPANY SUPPORT AGREEMENT This COMPANY SUPPORT AGREEMENT, dated as of April 5, 2023 (this “Agreement”), is entered into by and among the stockholders listed on Exhibit A hereto (each, a “Stockholder”), Clearday, Inc., a Delaware corporation (the “Company”), and Viveon Health Acquisition Corp., a Delaware corporation (“Parent”). Capitalized terms used but not defined in this Agreement |
|
| April 11, 2023 |
Form of Lock-Up Agreement, between the Holder (defined therein) and Viveon Health Acquisition Corp. Exhibit 10.3 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is dated as of [], 2023, by and between the undersigned stockholder (the “Holder”) and Viveon Health Acquisition Corp., a Delaware corporation (the “Parent”). A. Parent, VHAC2 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, Clearday, Inc., a Delaware corporation (the “Company”), and the Represe |
|
| April 11, 2023 |
Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) effective as of [], 2023, is made and entered into by and among Clearday, Inc. (formerly known as Viveon Health Acquisition Corp.), a Delaware corporation (the “Company”), each of the undersigned parties that are Pre-BC Investors (as defined below), and each of |
|
| April 11, 2023 |
Exhibit 10.2 COMPANY SUPPORT AGREEMENT This COMPANY SUPPORT AGREEMENT, dated as of April 5, 2023 (this “Agreement”), is entered into by and among the stockholders listed on Exhibit A hereto (each, a “Stockholder”), Clearday, Inc., a Delaware corporation (the “Company”), and Viveon Health Acquisition Corp., a Delaware corporation (“Parent”). Capitalized terms used but not defined in this Agreement |
|
| April 11, 2023 |
Exhibit 10.1 PARENT SUPPORT AGREEMENT This PARENT SUPPORT AGREEMENT, dated as of April 5, 2023 (this “Agreement”), is entered into by and among the stockholders listed on Exhibit A hereto (each, a “Stockholder”), Clearday, Inc., a Delaware corporation (the “Company”), and Viveon Health Acquisition Corp., a Delaware corporation (“Parent”). Capitalized terms used but not defined in this Agreement sh |
|
| April 11, 2023 |
Exhibit 10.1 PARENT SUPPORT AGREEMENT This PARENT SUPPORT AGREEMENT, dated as of April 5, 2023 (this “Agreement”), is entered into by and among the stockholders listed on Exhibit A hereto (each, a “Stockholder”), Clearday, Inc., a Delaware corporation (the “Company”), and Viveon Health Acquisition Corp., a Delaware corporation (“Parent”). Capitalized terms used but not defined in this Agreement sh |
|
| April 11, 2023 |
Form of Lock-Up Agreement, between the Holder (defined therein) and Viveon Health Acquisition Corp. Exhibit 10.3 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is dated as of [], 2023, by and between the undersigned stockholder (the “Holder”) and Viveon Health Acquisition Corp., a Delaware corporation (the “Parent”). A. Parent, VHAC2 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, Clearday, Inc., a Delaware corporation (the “Company”), and the Represe |
|
| April 11, 2023 |
Exhibit 2.1 EXECUTION VERSION MERGER AGREEMENT dated April 5, 2023 by and among Clearday, Inc., Clearday SR LLC, in the capacity as the Company Representative, Viveon Health Acquisition Corp., VHAC2 Merger Sub, Inc. and Viveon Health LLC, in the capacity as the SPAC Representative TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 Construction 17 ARTICLE II MERGER 18 2.1 Merger 1 |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| April 11, 2023 |
Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) effective as of [], 2023, is made and entered into by and among Clearday, Inc. (formerly known as Viveon Health Acquisition Corp.), a Delaware corporation (the “Company”), each of the undersigned parties that are Pre-BC Investors (as defined below), and each of |
|
| April 11, 2023 |
Exhibit 2.1 EXECUTION VERSION MERGER AGREEMENT dated April 5, 2023 by and among Clearday, Inc., Clearday SR LLC, in the capacity as the Company Representative, Viveon Health Acquisition Corp., VHAC2 Merger Sub, Inc. and Viveon Health LLC, in the capacity as the SPAC Representative TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 Construction 17 ARTICLE II MERGER 18 2.1 Merger 1 |
|
| April 11, 2023 |
425 1 form425.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of i |
|
| April 6, 2023 |
Investor Presentation dated April 2023. Exhibit 99.2 |
|
| April 6, 2023 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market CEO Jim Walesa will lead the combined company, Clearday, as Chief Executive Officer Jagi Gill, Chief Executive Officer and Chairman of Viveon Health, will join the Board of Directors of Clearday San Antonio, TX and Norcr |
|
| April 6, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| April 6, 2023 |
Exhibit 99.1 Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market CEO Jim Walesa will lead the combined company, Clearday, as Chief Executive Officer Jagi Gill, Chief Executive Officer and Chairman of Viveon Health, will join the Board of Directors of Clearday San Antonio, TX and Norcross, GA (April 6, 202 |
|
| April 6, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| April 6, 2023 |
Investor Presentation dated April 2023. Exhibit 99.2 |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Rep |
|
| February 28, 2023 |
VIVEON HEALTH ACQUISITION CORP. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road, Suite 200 Norcross, GA 30092 February 28, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Christine Westbrook Re: Viveon Health Acquisition Corp. Registrati |
|
| February 16, 2023 |
VHAQ / Viveon Health Acquisition Corp. / Meteora Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveon Health Acquisition Corporation (Name of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 92853V 106 (CUSIP Number) January 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 16, 2023 |
EX-99.1 2 vhaqex9901.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regula |
|
| February 14, 2023 |
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveon Health Acquisition Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 92853V106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2023 |
VHAQ / Viveon Health Acquisition Corp. / FIR TREE CAPITAL MANAGEMENT LP Passive Investment SC 13G 1 firtree-vhaq123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveon Health Acquisition Corp. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92853V106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 10, 2023 |
EX-99.1 2 viveonex9901.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regu |
|
| February 10, 2023 |
VHAQ / Viveon Health Acquisition Corp. / Meteora Capital, LLC - FORM SC 13G Passive Investment SC 13G 1 viveonsc13g.htm FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveon Health Acquisition Corporation (Name of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 92853V 106 (CUSIP Number) January 31, 2023 (Date of Event which Requires Filing of this Statement) C |
|
| February 3, 2023 |
Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. Exhibit 99.1 Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. Norcross, GA– , Feb. 03, 2023 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (the “Company” or “Viveon”), a special purpose acquisition company, announced today that it has unilaterally terminated its previously announced agreement and plan |
|
| February 3, 2023 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2023 Date of Report February 2, 2023 (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of i |
|
| February 3, 2023 |
Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. Exhibit 99.1 Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. Norcross, GA– , Feb. 03, 2023 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU) (the “Company” or “Viveon”), a special purpose acquisition company, announced today that it has unilaterally terminated its previously announced agreement and plan |
|
| February 3, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2023 Date of Report February 2, 2023 (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of i |
|
| January 25, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2023 Date of Report January 20, 2023 (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of i |
|
| January 25, 2023 |
Exhibit 99.1 VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Until February 3, 2023. NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company (the “Company”), today announced tha |
|
| January 25, 2023 |
EX-99.1 2 ea172084ex99-1viveon.htm PRESS RELEASE Exhibit 99.1 VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Until February 3, 2023. NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisi |
|
| January 25, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2023 Date of Report January 20, 2023 (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of i |
|
| December 28, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| December 28, 2022 |
As filed Second Amendment to the Company’s Amended and Restated Certificate of Incorporation. EX-3.1 2 ea170838ex3-1viveon.htm AS FILED SECOND AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “VIVEON HEALTH ACQUISITION CORP.”, FILED IN THIS OFFICE ON THE TWENTY-THIRD |
|
| December 28, 2022 |
EX-3.1 2 ea170838ex3-1viveon.htm AS FILED SECOND AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “VIVEON HEALTH ACQUISITION CORP.”, FILED IN THIS OFFICE ON THE TWENTY-THIRD |
|
| December 28, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) |
|
| December 22, 2022 |
EX-99.1 2 ea170747ex99-1viveon.htm PRESS RELEASE DATED DECEMBER 21, 2022 Exhibit 99.1 VIVEON HEALTH ACQUISITION CORP. Announces that Redemption Reversals in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Are Extended Until December 23, 2022. NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, |
|
| December 22, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 21, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (C |
|
| December 22, 2022 |
Exhibit 99.1 VIVEON HEALTH ACQUISITION CORP. Announces that Redemption Reversals in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Are Extended Until December 23, 2022. NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) - Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company (the ?Company?), today anno |
|
| December 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 21, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (C |
|
| November 23, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266123 Supplement No. 1 to Proxy Statement/Prospectus SUPPLEMENT No. 1 TO PROXY STATEMENT FOR SPECIAL MEETING OF VIVEON HEALTH ACQUISITION CORP. AND PROSPECTUS FOR SHARES OF COMMON STOCK OF VIVEON HEALTH ACQUISITION CORP. Viveon Health Acquisition Corp. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcros |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH A |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 17, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266123 PROSPECTUS PROXY STATEMENT FOR SPECIAL MEETING OF VIVEON HEALTH ACQUISITION CORP. AND PROSPECTUS FOR SHARES OF COMMON STOCK OF VIVEON HEALTH ACQUISITION CORP. Viveon Health Acquisition Corp. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross Georgia 30092 Tel: (404) 861-5393 To the Stockholders |
|
| November 14, 2022 |
Viveon Health Acquisition Corp. Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road, Suite 200 Norcross, GA 30092 November 14, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Christine Westbrook RE: Viveon Health Acquisition Corp. Amendment No. |
|
| November 14, 2022 |
VHAQ / Viveon Health Acquisition Corp. / Feis Lawrence Michael - SCHEDULE 13G/A Passive Investment OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number:3235-0145 Expires:Febuary 28, 2009 Estimated average burden hours per response ....10.4 SCHEDULE 13G Under the Securities and Exchange Act of 1934 (Amendment No. 1 )* Viveon Health Acquisition Corp. (Name of Issuer) Common stock, par value $ 0.0001 (Title of Class of Securities) 92853V106 (CUSIP Number) |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 ea168339-nt10qviveonhealth.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition |
|
| November 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (C |
|
| November 10, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (C |
|
| November 10, 2022 |
Exhibit 2.1 THIRD AMENDMENT TO MERGER AGREEMENT This Third Amendment to Merger Agreement (this ?Amendment?), dated as of November 10, 2022, is entered into by and among Suneva Medical, Inc., a Delaware corporation (the ?Company?), Viveon Health Acquisition Corp., a Delaware corporation (?Parent?), and VHAC Merger Sub, Inc., a Delaware corporation (?Merger Sub?). RECITALS WHEREAS, the Company, Pare |
|
| November 10, 2022 |
Exhibit 2.1 THIRD AMENDMENT TO MERGER AGREEMENT This Third Amendment to Merger Agreement (this ?Amendment?), dated as of November 10, 2022, is entered into by and among Suneva Medical, Inc., a Delaware corporation (the ?Company?), Viveon Health Acquisition Corp., a Delaware corporation (?Parent?), and VHAC Merger Sub, Inc., a Delaware corporation (?Merger Sub?). RECITALS WHEREAS, the Company, Pare |
|
| November 10, 2022 |
Exhibit 2.4 THIRD AMENDMENT TO MERGER AGREEMENT This Third Amendment to Merger Agreement (this ?Amendment?), dated as of November 10, 2022, is entered into by and among Suneva Medical, Inc., a Delaware corporation (the ?Company?), Viveon Health Acquisition Corp., a Delaware corporation (?Parent?), and VHAC Merger Sub, Inc., a Delaware corporation (?Merger Sub?). RECITALS WHEREAS, the Company, Pare |
|
| November 10, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-4 (Form Type) Viveon Health Acquisition Corp. |
|
| November 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 10, 2022 As filed with the U.S. Securities and Exchange Commission on November 10, 2022 Registration No. 333-266123 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viveon Health Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-278802 (State or Other Jurisdicti |
|
| November 10, 2022 |
Exhibit 99.1 PROXY CARD VIVEON HEALTH ACQUISITION CORP. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross, Georgia 30092 SPECIAL MEETING OF STOCKHOLDERS December 21, 2022 YOUR VOTE IS IMPORTANT FOLD AND DETACH HERE VIVEON HEALTH ACQUISITION CORP. THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON Decem |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| November 4, 2022 |
Form of Amended and Restated Certificate of Incorporation of Suneva Holdings, Inc. Exhibit 3.4 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Suneva Holdings, Inc. Jagi Gill hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Suneva Holdings, Inc., a Delaware corporation. TWO: The date of filing of said corporation?s original certificate of incorporation with the Delaware Secretary of State was August 7, 2020. THREE: The Amended and Res |
|
| November 4, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 3, 2022 As filed with the U.S. Securities and Exchange Commission on November 3, 2022 Registration No. 333-266123 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viveon Health Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-278802 (State or Other Jurisdictio |
|
| November 4, 2022 |
Exhibit 99.1 PROXY CARD VIVEON HEALTH ACQUISITION CORP. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross, Georgia 30092 SPECIAL MEETING OF STOCKHOLDERS [?], 2022 YOUR VOTE IS IMPORTANT FOLD AND DETACH HERE VIVEON HEALTH ACQUISITION CORP. THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON [?], 2022 The |
|
| November 4, 2022 |
Form of Suneva Medical, Inc. 2022. Employee Stock Purchase Plan. Exhibit 10.10 Suneva Medical, Inc. 2022 Employee Stock Purchase Plan Adopted by the Board of Directors: [ ], 2022 Approved by the Stockholders: [ ], 2022 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purch |
|
| November 4, 2022 |
Form of Amended and Restated Bylaws of Suneva Holdings, Inc. Exhibit 3.5 AMended and restated BYLAWS OF SUNEVA HOLDINGS, INC. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation?s |
|
| November 4, 2022 |
Form of Suneva Medical, Inc. 2022. Equity Incentive Plan. Exhibit 10.9 Suneva Medical, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: [ ], 2022 Approved by the Stockholders: [ ], 2022 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affil |
|
| November 3, 2022 |
CORRESP 1 filename1.htm 345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 November 3, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Newberry Re: Viveon Health Acquisition Corp. Amendment No. 1 to Registration Statement on Form S-4 Filed S |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 20, 2022 |
Form of Amended and Restated Certificate of Incorporation of Suneva Holdings, Inc. Exhibit 3.4 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Suneva Holdings, Inc. Jagi Gill hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Suneva Holdings, Inc., a Delaware corporation. TWO: The date of filing of said corporation?s original certificate of incorporation with the Delaware Secretary of State was August 7, 2020. THREE: The Amended and Res |
|
| September 20, 2022 |
Form of Amended and Restated Bylaws of Suneva Holdings, Inc. Exhibit 3.5 AMended and restated BYLAWS OF SUNEVA HOLDINGS, INC. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation?s |
|
| September 20, 2022 |
As filed with the U.S. Securities and Exchange Commission on September 19, 2022 As filed with the U.S. Securities and Exchange Commission on September 19, 2022 Registration No. 333-266123 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viveon Health Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-278802 (State or Other Jurisdict |
|
| September 19, 2022 |
345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 September 19, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Newberry Re: Viveon Health Acquisition Corp. Registration Statement on Form S-4 Filed July 13, 2022 File No. 333-266123 Dear Mr. |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH ACQU |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH ACQ |
|
| September 8, 2022 |
Viveon Health Acquisition Corp. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road, Suite 200 Norcross, GA 30092 Via Edgar September 8, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Gary Newberry and Mr. Daniel Gordon Re: Viveon Health Acquisition Corp. Form 10-K for |
|
| August 24, 2022 |
Viveon Health Acquisition Corp. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road, Suite 200 Norcross, GA 30092 Via Edgar August 24, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Gary Newberry and Mr. Daniel Gordon Re: Viveon Health Acquisition Corp. Form 10-K for th |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVE |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH ACQUIS |
|
| August 16, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| July 29, 2022 |
VHAQ / Viveon Health Acquisition Corp. / Feis Lawrence Michael - SCHEDULE 13G Passive Investment Schedule 13G OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 13, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 13, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commi |
|
| July 13, 2022 |
Consent of Ron Eastman to be named as a director. Exhibit 99.3 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Exhibit 99.1 PROXY CARD VIVEON HEALTH ACQUISITION CORP. c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross, Georgia 30092 SPECIAL MEETING OF STOCKHOLDERS [?], 2022 YOUR VOTE IS IMPORTANT FOLD AND DETACH HERE VIVEON HEALTH ACQUISITION CORP. THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON [?], 2022 The |
|
| July 13, 2022 |
Exhibit 21.1 List of Subsidiaries of VIVEON HEALTH ACQUISITION CORP. Viveon Health Merger Sub Inc. |
|
| July 13, 2022 |
Exhibit 10.30 SUPPLY AGREEMENT This Supply Agreement (the ?Agreement?) is made and entered into this 17?day of November, 2015 (the ?Effective Date?) by and between Merit Medical Systems, Inc., a Utah corporation with its principal place of business at 1600 West Merit Parkway, South Jordan, Utah 84095 (?Merit?) and Suneva Medical, Inc., a Delaware corporation with offices at 5780 Pacific Center Blv |
|
| July 13, 2022 |
Exhibit 10.32 CONFIDENTIAL SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (this ?Agreement? or ?Supply Agreement?) is made and entered effective as of the Effective Date (defined in the License Agreement) by and between Suneva Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 5870 Pacific Center Boulevard, San Diego, California 92121 (?Suneva?) a |
|
| July 13, 2022 |
Exhibit 10.37 Suneva Confidential AMENDED & RESTATED DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN SUNEVA MEDICAL, INC. AND HANGZHOU ST. NOVA TRADE CO., LTD Suneva Confidential THIS AMENDED & RESTATED DISTRIBUTION AND SUPPLY AGREEMENT (?Agreement?) is made as of this 6th day of June, 2017 (?Effective Date?) between SUNEVA MEDICAL, INC., a Delaware corporation with its principal office at 5870 Pacific |
|
| July 13, 2022 |
Exhibit 2.1 SECOND AMENDMENT TO MERGER AGREEMENT This Second Amendment to Merger Agreement (this ?Amendment?), dated as of July 13, 2022 is entered into by and among Suneva Medical, Inc., a Delaware corporation (the ?Company?), Viveon Health Acquisition Corp., a Delaware corporation (?Parent?), and VHAC Merger Sub, Inc., a Delaware corporation (?Merger Sub?). RECITALS WHEREAS, the Company, Parent |
|
| July 13, 2022 |
Exhibit 10.34 FIRST AMENDMENT TO LICENSE AGREEMENT This FIRST AMENDMENT TO LICENSE AGREEMENT (the ?Amendment?) is entered into as of March 20, 2020 (the ?Amendment Date?), by and among Suneva Medical, Inc., a Dela ware corporation (?Suneva?) and Healeon Medical, Inc., a California corporation (?Healeon?). Capitalized terms used in this Amendment and not otherwise defined in this Amendment have the |
|
| July 13, 2022 |
Form of Employment Agreement between Suneva Medical, Inc. and Pamela Misajon. Exhibit 10.21 SUNEVA MEDICAL, INC. EMPLOYMENT AGREEMENT THE EMPLOYMENT AGREEMENT (the ?Agreement?) is made as of January , 2019 (the ?Effective Date?), between Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Pamela Misajon (the ?Employee?). The Company and Employee are sometimes hereinafter referred to individually as a ?Party? and together as ?Parties.? WHEREAS, Employee has bee |
|
| July 13, 2022 |
Exhibit 10.19 NON-DISCLOSURE, INTELLECTUAL PROPERTY PROTECTION AND NON-SOLICITATION AGREEMENT This Agreement (?Agreement?) between Suneva Medical, Inc., a Delaware corporation, and its direct and indirect affiliates and subsidiaries (hereinafter collectively referred to as the ?Company?) and the undersigned employee (?Employee?) is entered into and shall be effective as of the Employee?s employmen |
|
| July 13, 2022 |
Suneva Medical, Inc. Offer Letter (Michael Brower) dated February 15, 2022. Exhibit 10.23 February 15, 2022 Michael Brower 3482 Paseo Ancho Carlsbad, CA 92009 Dear Michael: On behalf of Suneva Medical, Inc. (the ?Company?), I am pleased to offer you a full-time position as Chief Financial Officer, reporting Pat Altavilla , President & Chief Executive Officer. We anticipate your start date will be Monday, February 28, 2022. We are confident that you will play an important |
|
| July 13, 2022 |
Form of Quality Agreement, dated December 6, 2018, between Puregraft LLC and Suneva Medical Inc. Exhibit 10.29 PUREGRAFT QUALITY AGREEMENT Approved by: Signature: Date: 12/06/2018 Suneva Medical Inc. Name Preston Romm Job Title: CEO Approved by: Signature: Date: 6 DEC 2018 Puregraft LLC Name: Bradford Conlan Job Title: CEO QF0688 Rev. B Page 1 of 6 Effective Date:12/3/2018 QUALITY AGREEMENT THIS AGREEMENT is made the 6 day of December 2018, BETWEEN: Puregraft LLC., a Delaware Limited-Liabilit |
|
| July 13, 2022 |
Consent of Demetrios Logothetis to be named as a director. Exhibit 99.6 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Exhibit 10.27 DATED December 11, 2020 supply and distribution agreement between Circa Skin Ltd and Suneva Medical, Inc This Agreement is dated this 11th day of December 2020 Between (1) Circa Skin Ltd, incorporated and registered in England & Wales with company number 12684331 whose registered office is at Flat 4, 31 Charles Road, West Ealing, London W13 0ND (Supplier); and (2) Suneva Medical, Inc |
|
| July 13, 2022 |
Exhibit 10.36 Distribution Agreement This AGREEMENT (?Agreement?) is made on 20 March 2020 between: Sinclair Pharma US Inc., a company established and existing under the laws of California, USA, having its place of business at 1 Technology Drive, Unit 134, Irvine, CA 92618, USA (?Company?); and Suneva Medical, Inc., a company established and existing under the laws of Delaware, USA, having its pri |
|
| July 13, 2022 |
Consent of Vince Ippolito to be named as a director. Exhibit 99.5 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Consent of Jagi Gill to be named as a director. Exhibit 99.4 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Exhibit 10.28 DISTRIBUTION AGREEMENT This Distribution Agreement (this ?Agreement?) is entered into and dated effective as of August 28, 2020 (the ?Effective Date?) by and between Neauvia North America, Inc., a Delaware corporation (?Neauvia?), and Suneva Medical, Inc., a Delaware corporation (?Distributor?). Distributor and Neauvia are sometimes individually referred to herein as a ?Party? and co |
|
| July 13, 2022 |
Exhibit 10.31 SUPPLY AND DISTRIBUTION AGREEMENT THIS SUPPLY AND DISTRIBUTION AGREEMENT (the ?Agreement?) is entered into as of 31st March, 2020 (the ?Effective Date?) by and between Sanwell Medical Equipment Co. Ltd., a Shanghai corporation having its primary office and place of business located at 2B88, No,561 SanMen RD, Baoshan District, Shanghai, China. 200439 (?Supplier??) and Suneva Medical I |
|
| July 13, 2022 |
Form of Employment Agreement between Suneva Medical, Inc. and Brian Pilcher. Exhibit 10.20 SUNEVA MEDICAL, INC. EMPLOYMENT AGREEMENT THE EMPLOYMENT AGREEMENT (the ?Agreement?) is made as of February , 2019 (the ?Effective Date?), between Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Brian Pilcher (the ?Employee?). The Company and Employee are sometimes hereinafter referred to individually as a ?Party? and together as ?Parties.? WHEREAS, the Company desi |
|
| July 13, 2022 |
Exhibit 2.2 FIRST AMENDMENT TO MERGER AGREEMENT This First Amendment to Merger Agreement (this ?Amendment?), dated as of February 9, 2022 is entered into by and among Suneva Medical, Inc., a Delaware corporation (the ?Company?), Viveon Health Acquisition Corp., a Delaware corporation (?Parent?), and VHAC Merger Sub, Inc., a Delaware corporation (?Merger Sub?). RECITALS WHEREAS, the Company, Parent |
|
| July 13, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-4 (Form Type) Viveon Health Acquisition Corp. |
|
| July 13, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 13, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viveon Health Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-278802 (State or Other Jurisdiction of Incorporation or Organization) (Primary Stand |
|
| July 13, 2022 |
Consent of Brian Chee to be named as a director. Exhibit 99.8 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Consent of Patricia Altavilla to be named as a director. Exhibit 99.2 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Exhibit 10.33 CONFIDENTIAL EXECUTION VERSION LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) is made and entered into as of the ?Effective Date? (defined below) by and between Healeon Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 1111 Rancho Conejo Blvd #204, Newbury Park, CA 91320 and its wholly-owned subsidiary Healeon M |
|
| July 13, 2022 |
Exhibit 10.26 FIRST AMENDMENT TO LOAN Documents This First Amendment to Loan Documents (this ?Amendment?) is entered into as of May 10, 2022, by and between AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (?Lender?) and SUNEVA MEDICAL, INC., a Delaware corporation (?Borrower?). RECITALS Borrower and Lender are parties to those certain Loan Documents dated as of August 24, 2 |
|
| July 13, 2022 |
Consent of Dennis Condon to be named as a director. Exhibit 99.7 July 13, 2022 Viveon Health Acquisition Corp. Spalding Exchange 3953 Holcomb Bridge Road #200 Norcross, GA 30092 Consent to Reference in Registration Statement Viveon Health Acquisition Corp. (the ?Company?) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), as of |
|
| July 13, 2022 |
Exhibit 10.25 SUPPLEMENT to the Loan and Security Agreement dated as of August 24, 2021 between SUNEVA MEDICAL, INC. (?Borrower?) and Avenue Venture Opportunities Fund, L.P. (?Lender?) This is a Supplement identified in the document entitled Loan and Security Agreement, dated as of August 24, 2021 (as amended, restated, supplemented and modified from time to time, the ?Loan and Security Agreement? |
|
| July 13, 2022 |
Exhibit 10.24 LOAN AND SECURITY AGREEMENT Dated as of August 24, 2021 between SUNEVA MEDICAL, INC., a Delaware corporation, as ?Borrower?, and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership, as ?Lender? LOAN AND SECURITY AGREEMENT Borrower and Lender have entered or anticipate entering into one or more transactions pursuant to which Lender agrees to make available to Borro |
|
| July 13, 2022 |
Exhibit 10.22 SUNEVA MEDICAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of (the ?Effective Date?), between Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Patricia Altavilla (the ?Employee?). This Agreement amends and restates in its entirety that certain EMPLOYMENT AGREEMENT dated September 19, 201 |
|
| July 13, 2022 |
Exhibit 10.38 Suneva Confidential DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN SUNEVA MEDICAL, INC. AND PACIFIC PHARMA CORPORATION Suneva Confidential DISTRIBUTION AND SUPPLY AGREEMENT made as of this 29th day of March, 2012 (?Effective Date?) between SUNEVA MEDICAL, INC., a Delaware corporation with its principal office at 5870 Pacific Center Blvd, San Diego, CA 92121 (hereinafter called ?SUNEVA?) a |
|
| July 13, 2022 |
Exhibit 10.35 CONFIDENTIAL EXCLUSIVE DISTRIBUTION AGREEMENT THIS EXCLUSIVE DISTRIBUTION AGREEMENT (?Agreement?) is made and entered into effective as of the date the last party hereto signs as shown on the signature page (?Effective Date?), and Is by and between Aurastem Technologies, LLC., a Delaware company having its primary office and place of business at 420 Stevens Avenue, Suite 220, Solana |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH ACQUI |
|
| May 27, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2022 |
EX-99.1 2 ea160741ex99-1viveon.htm PRESS RELEASE, DATED MAY 27, 2022 Exhibit 99.1 Viveon Health Acquisition Corp. Receives Noncompliance Notice Regarding Late Form 10-Q Filing From the NYSE New York, May 27, 2022 /GLOBE NEWSWIRE/ - Viveon Health Acquisition Corp. (NYSE: “VHAQU” or the “Company”) announces that on May 24, 2022, as a result of its inability to timely file with the Securities and Exc |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 ea160024-nt10qviveonhealth.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Rep |
|
| April 8, 2022 |
SC 13G/A 1 karpus-sch13g18608.htm KARPUS INVESTMENT MGT / (VHAQ) VIVEON HEALTH ACQ - SCHEDULE 13G/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Viveon Health Acquisition Corp. (Name of Issuer) Common (Title of Class of Securities) 92853V106 (CUSIP Number) March 31, 2022 (Date of Event Which R |
|
| March 31, 2022 |
Exhibit 4.7 DESCRIPTION OF SECURITIES OF VIVEON The following description of capital stock of Viveon Health Acquisition Corp. (?Viveon?, or the ?Company?) and provisions of Viveon?s current amended and restated certificate of incorporation, as amended (the ?Existing Charter?), bylaws and the Delaware General Corporation Law (?DGCL?) are summaries and are qualified in their entirety by reference to |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVEON HEALTH ACQUISITIO |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 3) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVE |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2022 VIVEON HEALTH ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Com |
|
| March 24, 2022 |
EX-10.1 3 ea157309ex10-1viveonhealth.htm FORM OF PROMISSORY NOTE Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY |
|
| March 24, 2022 |
Exhibit 10.2 THESE SECURITIES AND ANY SECURITIES ISSUABLE UPON THE EXERCISE OF THIS SECURITY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| March 24, 2022 |
Exhibit 10.3 To: Viveon Health Acquisition Corp. LLC (the ?Company?) The undersigned (the ?Subscriber?), intending to be legally bound, hereby subscribes for up to $ principal amount of Senior Notes due December 31, 2022, in the form of Exhibit A hereto (the ?Notes?), together with a common stock purchase warrant to acquire one share of common stock, par value $0.001 per share (the ?Common Stock?) |
|
| March 24, 2022 |
Exhibit 10.4 AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 1 (this ?Amendment?), dated as of March 23, 2022, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the ?Company?) and Continental Stock Transfer & Trust Company, as trustee (?Trustee?). All terms used but not defined herein shall have the mea |
|
| March 24, 2022 |
EX-3.1 2 ea157309ex3-1viveonhealth.htm AS FILED AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 |
|
| March 18, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of ?incorporation) (Co |
|
| March 18, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Co |
|
| March 17, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2022 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Viveon Health Acquisition Corp. (Name of Issuer) Common (Title of Class of Securities) 92853V106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 9, 2022 |
Transcript of Interview with Pat Altavilla, January 12, 2022 Exhibit 99.1 Transcript of Interview with Pat Altavilla, January 12, 2022 Nicole Petallides It?s time for our spotlight now. We are spotlighting Suneva Medical. The regenerative aesthetics company announced its SPAC merger agreement this morning. Joining us with all the details is the company?s CEO, Pat Altavilla. Thank you so much for being with us. Very excited that you could be on with us today |
|
| February 9, 2022 |
Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal Exhibit 99.2 Bloomberg Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal By Michelle F Davis January 12, 2022 Suneva Medical Inc., which sells beauty and anti-aging products to doctors’ offices, has agreed to go public through a merger with blank-check company Viveon Health Acquisition Corp. The deal values the combined company at about $511 million including debt, according to a stat |
|
| February 9, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| February 9, 2022 |
EX-99.3 4 ea155112ex99-3viveon.htm PRESS RELEASE ISSUED FEBRUARY 8, 2022 Exhibit 99.3 Suneva Surpasses 1 Million Syringes of Bellafill® Distributed Since the Biostimulator’s Inception SAN DIEGO, Feb. 8, 2022 /PRNewswire/ - Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, to |
|
| February 9, 2022 |
Other Events, Financial Statements and Exhibits United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| February 9, 2022 |
Transcript of Interview with Pat Altavilla, January 12, 2022 Exhibit 99.1 Transcript of Interview with Pat Altavilla, January 12, 2022 Nicole Petallides It’s time for our spotlight now. We are spotlighting Suneva Medical. The regenerative aesthetics company announced its SPAC merger agreement this morning. Joining us with all the details is the company’s CEO, Pat Altavilla. Thank you so much for being with us. Very excited that you could be on with us today |
|
| February 9, 2022 |
Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal Exhibit 99.2 Bloomberg Aesthetics Firm Suneva Is in Talks for Viveon Health SPAC Deal By Michelle F Davis January 12, 2022 Suneva Medical Inc., which sells beauty and anti-aging products to doctors? offices, has agreed to go public through a merger with blank-check company Viveon Health Acquisition Corp. The deal values the combined company at about $511 million including debt, according to a stat |
|
| February 9, 2022 |
EX-99.3 4 ea155112ex99-3viveon.htm PRESS RELEASE ISSUED FEBRUARY 8, 2022 Exhibit 99.3 Suneva Surpasses 1 Million Syringes of Bellafill® Distributed Since the Biostimulator’s Inception SAN DIEGO, Feb. 8, 2022 /PRNewswire/ - Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, to |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G AMENDMENT NO. |
|
| January 28, 2022 |
VHAQ / Viveon Health Acquisition Corp. / Weiss Asset Management LP Passive Investment 2.22% CUSIP NO. 92853V106 SCHEDULE 13G/A PAGE 1 OF 10 PAGES =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIVEON HEALTH ACQUISITION CORP. - (Name of Issuer) Common stock, $0.0001 par value per share - (Title of Class o |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| January 13, 2022 |
Exhibit 2.1 EXECUTION COPY MERGER AGREEMENT dated January 12, 2022 by and among Suneva Medical, Inc., Viveon Health Acquisition Corp. and VHAC Merger Sub, Inc. Table of Contents Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 Construction 16 ARTICLE II MERGER 17 2.1 Merger 17 2.2 Merger Effective Time 17 2.3 Effect of the Merger 17 2.4 U.S. Tax Treatment 18 2.5 Certificate of Incorporation; Byl |
|
| January 13, 2022 |
Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) effective as of the 12th day of January, 2022, is made and entered into by and among Suneva Holdings, Inc. (formerly known as Viveon Health Acquisition Corp.), a Delaware corporation (the ?Company?), each of the undersigned parties that are Pre-BC Investors (as |
|
| January 13, 2022 |
Exhibit 10.2 COMPANY STOCKHOLDER SUPPORT AGREEMENT 1 This COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of January 12, 2022 (this ?Agreement?), is entered into by and among the stockholders listed on Exhibit A hereto (each, a ?Stockholder?), Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Viveon Health Acquisition Corp., a Delaware corporation (?Parent?). Capitalized terms used |
|
| January 13, 2022 |
EX-10.1 3 ea153264ex10-1viveon.htm FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT DATED AS OF JANUARY 12, 2022, BY AND AMONG VIVEON HEALTH ACQUISITION CORP., SUNEVA MEDICAL, INC. AND CERTAIN STOCKHOLDERS OF VIVEON HEALTH ACQUISITION CORP. Exhibit 10.1 PARENT STOCKHOLDER SUPPORT AGREEMENT This PARENT STOCKHOLDER SUPPORT AGREEMENT, dated as of January 12, 2022 (this “Agreement”), is entered into by an |
|
| January 13, 2022 |
EX-2.1 2 ea153264ex2-1viveon.htm MERGER AGREEMENT DATED AS OF JANUARY 12, 2022, BY AND AMONG SUNEVA MEDICAL, INC., VIVEON HEALTH ACQUISITION CORP. AND VHAC MERGER SUB, INC Exhibit 2.1 EXECUTION COPY MERGER AGREEMENT dated January 12, 2022 by and among Suneva Medical, Inc., Viveon Health Acquisition Corp. and VHAC Merger Sub, Inc. Table of Contents Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 |
|
| January 13, 2022 |
EX-99.1 7 ea153264ex99-1viveon.htm PRESS RELEASE ISSUED BY VIVEON ON JANUARY 12, 2022 Exhibit 99.1 Suneva Medical Inc. and Viveon Health Acquisition Corp. Announce Merger Agreement to Create a Leading Regenerative Aesthetics Company CEO Pat Altavilla will lead the combined company, Suneva Medical, as Chief Executive Officer Jagi Gill, Chief Executive Officer and Chairman of Viveon Health, will joi |
|
| January 13, 2022 |
Exhibit 99.1 Suneva Medical Inc. and Viveon Health Acquisition Corp. Announce Merger Agreement to Create a Leading Regenerative Aesthetics Company CEO Pat Altavilla will lead the combined company, Suneva Medical, as Chief Executive Officer Jagi Gill, Chief Executive Officer and Chairman of Viveon Health, will join the Board of Directors of Suneva Medical San Diego, CA and Norcross, GA (January 12, |
|
| January 13, 2022 |
Exhibit 10.2 COMPANY STOCKHOLDER SUPPORT AGREEMENT 1 This COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of January 12, 2022 (this ?Agreement?), is entered into by and among the stockholders listed on Exhibit A hereto (each, a ?Stockholder?), Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Viveon Health Acquisition Corp., a Delaware corporation (?Parent?). Capitalized terms used |
|
| January 13, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of ?incorporation) ( |
|
| January 13, 2022 |
Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) effective as of the 12th day of January, 2022, is made and entered into by and among Suneva Holdings, Inc. (formerly known as Viveon Health Acquisition Corp.), a Delaware corporation (the ?Company?), each of the undersigned parties that are Pre-BC Investors (as |
|
| January 13, 2022 |
EX-10.3 5 ea153264ex10-3viveon.htm FORM OF LOCK-UP AGREEMENT, DATED AS OF JANUARY 12, 2022 BETWEEN THE HOLDER AND VIVEON HEALTH ACQUISITION CORP. Exhibit 10.3 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is dated as of January 12, 2022 by and between the undersigned stockholder (the “Holder”) and Viveon Health Acquisition Corp., a Delaware corporation (the “Parent”). A. Parent, VHAC |
|
| January 13, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) ( |
|
| January 13, 2022 |
Exhibit 99.2 Business Co m bination Summary January 2022 ACTUAL SUNEVA PATIENTS Disclaimer 2 This presentation (?Presentation?) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Viveon Health Acquisition Corp . (?Viveon?) and Suneva Medical, Inc . (together with its |
|
| January 13, 2022 |
Exhibit 10.3 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this ?Agreement?) is dated as of January 12, 2022 by and between the undersigned stockholder (the ?Holder?) and Viveon Health Acquisition Corp., a Delaware corporation (the ?Parent?). A. Parent, VHAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, and Suneva Medical, Inc., a Delaware corporation (the ?Company?), |
|
| January 13, 2022 |
EX-99.2 8 ea153264ex99-2viveon.htm INVESTOR PRESENTATION DATED DECEMBER 2021 Exhibit 99.2 Business Co m bination Summary January 2022 ACTUAL SUNEVA PATIENTS Disclaimer 2 This presentation (“Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Viveon Healt |
|
| January 13, 2022 |
Exhibit 10.1 PARENT STOCKHOLDER SUPPORT AGREEMENT This PARENT STOCKHOLDER SUPPORT AGREEMENT, dated as of January 12, 2022 (this ?Agreement?), is entered into by and among the stockholders listed on Exhibit A hereto (each, a ?Stockholder?), Suneva Medical, Inc., a Delaware corporation (the ?Company?), and Viveon Health Acquisition Corp., a Delaware corporation (?Parent?). Capitalized terms used but |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.2) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39827 VIVEO |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39827 VIVEON HEALTH A |
|
| November 16, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2021 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (C |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? T |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39827 VIVEON HEALTH ACQ |
|
| July 2, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 2, 2021 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commis |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39827 VIVEON HEALTH AC |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39827 VIVEON HEALT |
|
| July 2, 2021 |
Exhibit 10.9 JOINDER AGREEMENT The undersigned, Demetrios Logothetis (the ?Joining Party?), is executing and delivering this Joinder Agreement with respect to the Stock Escrow Agreement, dated as of December 22, 2020, between the Viveon Health Acquisition Corp. (the ?Company?) and Continental Stock Transfer & Trust Co., (the ?Transfer Agent?) and the other stockholders of the Company party thereto |
|
| May 28, 2021 |
Exhibit 99.1 Viveon Health Acquisition Corp. Receives Noncompliance Notice Regarding Late Form 10-Q Filing From the NYSE New York, May 28, 2021 /GLOBE NEWSWIRE/ - Viveon Health Acquisition Corp. (NYSE: ?VHAQU? or the ?Company?) announces that on May 25, 2021, as a result of its inability to timely file with the Securities and Exchange Commission ("SEC") its Quarterly Report on Form 10-Q for the fi |
|
| May 28, 2021 |
Financial Statements and Exhibits United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 25, 2021 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Commis |
|
| May 17, 2021 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Repo |
|
| April 30, 2021 |
EX-10.1 2 ea140111ex10-1viveon.htm LETTER AGREEMENT, DATED APRIL 28, 2021, AMONG THE COMPANY AND MR. LOGOTHETIS Exhibit 10.1 April 30, 2021 Viveon Health Acquisition Corp c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross Georgia 30092 Chardan Capital Markets, LLC 17 State Street, 21st Floor New York, NY 10004 Re: Initial Public Offering Gentlemen: This l |
|
| April 30, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2021 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Comm |
|
| April 26, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 20, 2021 Date of Report (Date of earliest event reported) Viveon Health Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39827 85-2788202 (State or other jurisdiction of incorporation) (Comm |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39827 VIVEON HEALTH ACQUISITION CORP. |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001 39827 CUSIP NUMBER 92853V 106 (Check One): xForm 10-K ?Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transiti |
|
| February 12, 2021 |
VIVEON HEALTH ACQUISITION CORP. =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 12, 2021 |
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveon Health Acquisition Corp. (Name of Issuer) Units (Title of Class of Securities) 92853V205 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
